Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.
about
Biologics registers in RA: methodological aspects, current role and future applications.Successful Use of Tocilizumab in a Patient with Coexisting Rheumatoid Arthritis and Ulcerative ColitisThe usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study.Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritisProfile of sarilumab and its potential in the treatment of rheumatoid arthritis.A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexateTocilizumab: A Review in Rheumatoid Arthritis.Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry.Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example.
P2860
Q30234303-744C2D00-1675-46ED-AF5D-9E2F6FDA61C1Q37366588-729FF770-B569-4828-8B25-CCAB98885770Q37562571-5581CB56-62AE-44E9-96FE-99AFAA0D1772Q37587403-D31DACB5-DCBA-46A9-B5FC-8AADE2DFED6AQ37622219-90C9B531-2A11-41E0-AB74-C9C7A194417FQ38745066-8084EEFC-FC2E-48C0-9B4F-B883136CE40AQ40372208-0C38AD85-43CA-49BF-9F70-EA26220DE5FAQ43280791-8776CA1B-1D9E-4E4E-BE9F-3A454B79AB1CQ47104450-9511CCA4-7026-42DB-AB22-C0409280923AQ47276595-3005C9F9-C0A2-4652-BA99-D27AD24211DBQ47367453-671D1B46-8E99-4CBC-ACFC-BFFFD58490D9Q55338290-8C37132A-A4CD-440B-8DFF-7A7D5C4B487A
P2860
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 September 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effectiveness of tocilizumab w ...... European collaborative study.
@en
Effectiveness of tocilizumab w ...... European collaborative study.
@nl
type
label
Effectiveness of tocilizumab w ...... European collaborative study.
@en
Effectiveness of tocilizumab w ...... European collaborative study.
@nl
prefLabel
Effectiveness of tocilizumab w ...... European collaborative study.
@en
Effectiveness of tocilizumab w ...... European collaborative study.
@nl
P2093
P2860
P50
P1476
Effectiveness of tocilizumab w ...... European collaborative study.
@en
P2093
Dan C Nordström
Elisabeth Lie
Ellen-Margrethe Hauge
Galina Lukina
Helena Canhao
Ioan Ancuta
M Victoria Hernández
Matija Tomšič
Myriam Riek
Piet L M C van Riel
P2860
P304
P356
10.1136/ANNRHEUMDIS-2015-207760
P407
P50
P577
2015-09-15T00:00:00Z